Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Aiwei Bi"'
Autor:
Nan Jin, Aiwei Bi, Xiaojing Lan, Jun Xu, Xiaomin Wang, Yingluo Liu, Ting Wang, Shuai Tang, Hanlin Zeng, Ziqi Chen, Minjia Tan, Jing Ai, Hua Xie, Tao Zhang, Dandan Liu, Ruimin Huang, Yue Song, Elaine Lai-Han Leung, Xiaojun Yao, Jian Ding, Meiyu Geng, Shu-Hai Lin, Min Huang
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Cancer subtypes may have distinct metabolic vulnerabilities that can be exploited for therapeutic interventions. Here, the authors show that in lung cancer, genetic activation of distinct oncogenic receptor tyrosine kinases results in unique metaboli
Externí odkaz:
https://doaj.org/article/9657645615f24b61be1f24096a3bc13c
Autor:
Jingyao Wang, Shaoqing Zhou, Yan Cheng, Lin Cheng, Ying Qin, Zhenfeng Zhang, Aiwei Bi, Huaijiang Xiang, Xinheng He, Xiaoxu Tian, Wenbin Liu, Jian Zhang, Chao Peng, Zhengjiang Zhu, Min Huang, Ying Li, Guanglei Zhuang, Li Tan
Publikováno v:
Journal of Medicinal Chemistry. 66:2608-2621
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f75815353d9b23f4d6f8fa7b78359260
https://doi.org/10.1021/acs.jmedchem.2c01563
https://doi.org/10.1021/acs.jmedchem.2c01563
Publikováno v:
International Journal of Molecular Medicine
The prognosis of high-risk neuroblastoma remains poor. Clinical first-line drugs for treating neuroblastoma have been developed over the previous half-century; however, progress in the identification of new drugs with high efficiency is required. Buf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e01eb328345cd6c49833c844d098098d
https://doi.org/10.3892/ijmm.2020.4745
https://doi.org/10.3892/ijmm.2020.4745
Autor:
Yue Song, Xiao-Jun Yao, Xiaomin Wang, Hanlin Zeng, Nan Jin, Ruimin Huang, Minjia Tan, Ting Wang, Elaine Lai-Han Leung, Ziqi Chen, Tao Zhang, Jing Ai, Yingluo Liu, Shuai Tang, Jian Ding, Min Huang, Hua Xie, Aiwei Bi, Jun Xu, Dandan Liu, Meiyu Geng, Lan Xiaojing, Shuhai Lin
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Nature Communications
Nature Communications
One of the biggest hurdles for the development of metabolism-targeted therapies is to identify the responsive tumor subsets. However, the metabolic vulnerabilities for most human cancers remain unclear. Establishing the link between metabolic signatu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9d642978bd44d7d3060aa1128ab509d
http://link.springer.com/article/10.1038/s41467-019-10427-2
http://link.springer.com/article/10.1038/s41467-019-10427-2
Autor:
Aiwei Bi, Meiyu Geng, Huang Min, Jia Liu, Shuhai Lin, Jun Xu, Shuai Tang, Jian Ding, Matthew Shou, Nan Jin, Lan Xiaojing
Publikováno v:
Cancer Research. 80:3737-3737
Mutant isocitrate dehydrogenase (mIDH), with a gain-of-function in the production of an oncometabolite (R)-2-hydroxyglutarate (2-HG), is considered as a promising target for cancers carrying IDH mutations. IDH1 mutations, typically involving an amino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bd264b41726ac68987c1c5bb733a923
https://doi.org/10.1158/1538-7445.am2020-3737
https://doi.org/10.1158/1538-7445.am2020-3737
Autor:
Jian Ding, Jun Xu, Meiyu Geng, Qiaoshi Lian, Bing Sun, Min Huang, Aiwei Bi, Shanshan Yan, Honghua Ding, Xiaoyu Sun
Publikováno v:
Cell research. 27(6)
Chemotherapies are known often to induce severe gastrointestinal tract toxicity but the underlying mechanism remains unclear. This study considers the widely applied cytotoxic agent irinotecan (CPT-11) as a representative agent and demonstrates that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7b4a2beaf650316485ab51343b3cd99
https://pubmed.ncbi.nlm.nih.gov/28409562
https://pubmed.ncbi.nlm.nih.gov/28409562